Prediabetes Market Size, Share & Trends Report

Prediabetes Market Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones), By Age Group (Children, Adult), By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-4-68040-221-4
Number of Pages: 134
Format: Electronic (PDF)

Historical Range: 2018 - 2022
Industry: Healthcare

Market Segmentation

Prediabetes Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Diguanide
- Thiazolidinediones
- Glucagon-like peptide-1 agonists (GLP-1)
- SGLT2 inhibitors
- DPP-4 inhibitors
- Others
Prediabetes Age group Outlook (Revenue, USD Million, 2018 - 2030)
- Children (12-18 years)
- Adults (18-49)
- Elderly (50+)
Prediabetes Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Prediabetes Market, by Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - North America Prediabetes Market, by Age group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - U.S.
    - U.S. Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - U.S. Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Canada
    - Canada Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Canada Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- Europe
  - Europe Prediabetes Market, by Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - Europe Prediabetes Market, by Age group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - UK
    - UK Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - UK Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Germany
    - Germany Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Germany Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - France
    - France Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - France Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Italy
    - Italy Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Italy Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Spain
    - Spain Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Spain Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Denmark
    - Denmark Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Denmark Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Sweden
    - Sweden Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Sweden Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Norway
    - Norway Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Norway Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- Asia Pacific
  - Asia Pacific Prediabetes Market, by Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - Asia Pacific Prediabetes Market, by Age group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - Japan
    - Japan Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Japan Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - China
    - China Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - China Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - India
    - India Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - India Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Australia
    - Australia Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Australia Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - South Korea
    - South Korea Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - South Korea Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Thailand
    - Thailand Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Thailand Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- Latin America
  - Latin America Prediabetes Market, by Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - Latin America Prediabetes Market, by Age group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - Brazil
    - Brazil Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Brazil Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Mexico
    - Mexico Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Mexico Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Argentina
    - Argentina Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Argentina Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
- MEA
  - MEA Prediabetes Market, by Drug Class
    - Diguanide
    - Thiazolidinediones
    - Glucagon-like peptide-1 agonists (GLP-1)
    - SGLT2 inhibitors
    - DPP-4 inhibitors
    - Others
  - MEA Prediabetes Market, by Age group
    - Children (12-18 years)
    - Adults (18-49)
    - Elderly (50+)
  - South Africa
    - South Africa Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - South Africa Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Saudi Arabia
    - Saudi Arabia Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Saudi Arabia Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - UAE
    - UAE Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - UAE Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)
  - Kuwait
    - Kuwait Prediabetes Market, by Drug Class
      - Diguanide
      - Thiazolidinediones
      - Glucagon-like peptide-1 agonists (GLP-1)
      - SGLT2 inhibitors
      - DPP-4 inhibitors
      - Others
    - Kuwait Prediabetes Market, by Age group
      - Children (12-18 years)
      - Adults (18-49)
      - Elderly (50+)

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.